Itapetininga, Brazil
Itapetininga, Brazil

Time filter

Source Type

« Nous sommes ravis de ce vote de confiance. La reconnaissance de notre travail par la DTRA renforce la position de MeMed en tant que leader mondial des diagnostics basés sur une approche immunologique des maladies infectieuses », a déclaré Eran Eden, PhD, PDG de MeMed.  « Cet effort conjoint, en plus de notre collaboration grandissante avec d'autres parties prenantes internationales des secteurs industriel et gouvernemental, facilitera la disponibilité mondiale de nos tests visant à lutter contre la résistance aux antimicrobiens. » Au cours des huit dernières années, les cofondateurs de la société Kfir Oved, MD/PhD et Eran Eden, PhD ont collaboré avec des chercheurs et cliniciens de premier plan du monde entier pour étudier les changements qui se déroulent dans le système immunitaire humain lorsqu'il lutte contre des infections, dans le but de développer une signature immunitaire humaine qui reconnaisse de façon précise la différence entre les infections bactériennes et virales. ImmunoXpert™, la première génération de ce test novateur, est déjà utilisée et a été validée chez des milliers de patients*. La deuxième génération du test a impliqué le développement d'une nouvelle plateforme de point de service qui est facile d'utilisation et prend environ 15 minutes. « Cette collaboration va nous permettre d'accélérer l'achèvement de notre programme de plateforme de point de service », a commenté Kfir Oved, MD/PhD, directeur technique de MeMed. « En plus de permettre les mesures de notre test de distinction entre infections bactériennes et virales en seulement quelques minutes, cette nouvelle plateforme ouvre également la voie à une variété de mesures rapides de protéines multiplexes au point de service avec une précision de qualité de laboratoire, associée à de nombreuses applications. » « Le projet évaluera et étendra aussi notre menu de tests afin de détecter les infections précoces, même au stade présymptomatique d'une maladie, ce qui constitue actuellement un défi majeur pour contrôler les infections et les épidémies », a ajouté Tanya Gottlieb, PhD, vice-présidente des affaires scientifiques de MeMed. *Oved et al. Plos One, 2015 ; Eden et al. Journal of Infection, 2016 ; van Houten et el. Lancet Infectious Diseases, 2016. La Defense Threat Reduction Agency (DTRA) a été fondée en 1998 afin d'intégrer et concentrer les capacités du Département de la Défense (DoD) qui concernent la menace par des armes de destruction massive (ADM). La mission de la DTRA est de protéger les États-Unis et ses alliés contre les armes de destruction massive internationales et les menaces improvisées, en intégrant, synchronisant et fournissant une expertise, des technologies et des capacités. Pour en savoir plus sur la DTRA, rendez-vous sur le site http://www.dtra.mil. MeMed se consacre à améliorer la vie des patients à travers la recherche, le développement et la commercialisation de tests pionniers qui examinent l'état immunitaire du corps. Ses tests décodent les différentes réponses du système immunitaire face à différents états de santé et médicaux. La société se concentre sur la provision de solutions diagnostiques rapides, précises et exploitables pour les maladies infectieuses aigües et les troubles inflammatoires au sein de l'hôpital et de la communauté. Son test de première génération, ImmunoXpert™, a démontré la capacité de détecter avec précision si un patient est atteint d'une infection bactérienne ou virale, dans l'objectif de permettre aux médecins de prendre des décisions plus éclairées en matière de traitement antibiotique. ImmunoXpert est autorisé pour usage clinique dans l'Union européenne, en Suisse et en Israël. Il est actuellement en distribution pilote dans ces territoires avec un déploiement commercial plus important enclenché. Le test de deuxième génération de MeMed pour les test rapides (en seulement quelques minutes) au point de service est en cours de développement. Pour de plus amples informations, veuillez consulter le site http://www.me-med.com. Contact auprès des médias et développement des affaires : Asi Cohen-Dotan, PhD Tél. : +972-4-8500302 asi.cohen@me-med.com


« Nous sommes ravis de ce vote de confiance. La reconnaissance de notre travail par la DTRA renforce la position de MeMed en tant que leader mondial des diagnostics basés sur une approche immunologique des maladies infectieuses », a déclaré Eran Eden, PhD, PDG de MeMed.  « Cet effort conjoint, en plus de notre collaboration grandissante avec d'autres parties prenantes internationales des secteurs industriel et gouvernemental, facilitera la disponibilité mondiale de nos tests visant à lutter contre la résistance aux antimicrobiens. » Au cours des huit dernières années, les cofondateurs de la société Kfir Oved, MD/PhD et Eran Eden, PhD ont collaboré avec des chercheurs et cliniciens de premier plan du monde entier pour étudier les changements qui se déroulent dans le système immunitaire humain lorsqu'il lutte contre des infections, dans le but de développer une signature immunitaire humaine qui reconnaisse de façon précise la différence entre les infections bactériennes et virales. ImmunoXpert™, la première génération de ce test novateur, est déjà utilisée et a été validée chez des milliers de patients*. La deuxième génération du test a impliqué le développement d'une nouvelle plateforme de point de service qui est facile d'utilisation et prend environ 15 minutes. « Cette collaboration va nous permettre d'accélérer l'achèvement de notre programme de plateforme de point de service », a commenté Kfir Oved, MD/PhD, directeur technique de MeMed. « En plus de permettre les mesures de notre test de distinction entre infections bactériennes et virales en seulement quelques minutes, cette nouvelle plateforme ouvre également la voie à une variété de mesures rapides de protéines multiplexes au point de service avec une précision de qualité de laboratoire, associée à de nombreuses applications. » « Le projet évaluera et étendra aussi notre menu de tests afin de détecter les infections précoces, même au stade présymptomatique d'une maladie, ce qui constitue actuellement un défi majeur pour contrôler les infections et les épidémies », a ajouté Tanya Gottlieb, PhD, vice-présidente des affaires scientifiques de MeMed. *Oved et al. Plos One, 2015 ; Eden et al. Journal of Infection, 2016 ; van Houten et el. Lancet Infectious Diseases, 2016. La Defense Threat Reduction Agency (DTRA) a été fondée en 1998 afin d'intégrer et concentrer les capacités du Département de la Défense (DoD) qui concernent la menace par des armes de destruction massive (ADM). La mission de la DTRA est de protéger les États-Unis et ses alliés contre les armes de destruction massive internationales et les menaces improvisées, en intégrant, synchronisant et fournissant une expertise, des technologies et des capacités. Pour en savoir plus sur la DTRA, rendez-vous sur le site http://www.dtra.mil. MeMed se consacre à améliorer la vie des patients à travers la recherche, le développement et la commercialisation de tests pionniers qui examinent l'état immunitaire du corps. Ses tests décodent les différentes réponses du système immunitaire face à différents états de santé et médicaux. La société se concentre sur la provision de solutions diagnostiques rapides, précises et exploitables pour les maladies infectieuses aigües et les troubles inflammatoires au sein de l'hôpital et de la communauté. Son test de première génération, ImmunoXpert™, a démontré la capacité de détecter avec précision si un patient est atteint d'une infection bactérienne ou virale, dans l'objectif de permettre aux médecins de prendre des décisions plus éclairées en matière de traitement antibiotique. ImmunoXpert est autorisé pour usage clinique dans l'Union européenne, en Suisse et en Israël. Il est actuellement en distribution pilote dans ces territoires avec un déploiement commercial plus important enclenché. Le test de deuxième génération de MeMed pour les test rapides (en seulement quelques minutes) au point de service est en cours de développement. Pour de plus amples informations, veuillez consulter le site http://www.me-med.com. Contact auprès des médias et développement des affaires : Asi Cohen-Dotan, PhD Tél. : +972-4-8500302 asi.cohen@me-med.com


"Wir freuen uns über diesen Vertrauensbeweis. Die Anerkennung unserer Arbeit durch die DTRA stärkt die Positionierung von MeMed als Weltmarktführer auf dem Gebiet der immunbasierten Diagnostik von Infektionskrankheiten", bemerkte Dr. Eran Eden, CEO bei MeMed.  "Diese gemeinsame Anstrengung und unsere wachsende Zusammenarbeit mit anderen internationalen Interessenvertretern aus Industrie und Regierung wird die weltweite Verfügbarkeit unserer Tests zur Bekämpfung antimikrobieller Resistenzen ermöglichen." Während der letzten acht Jahre haben die Unternehmensmitgründer Dr. med. Kfir Oved und Dr. Eran Eden mit führenden Forschern und Klinikern aus der ganzen Welt zusammengearbeitet, um die Veränderungen zu untersuchen, die im menschlichen Immunsystem stattfinden, wenn es Infektionen bekämpft, und um eine menschliche Immunsignatur zu entwickeln, die den Unterschied zwischen bakteriellen und Virusinfektionen genau erkennt. ImmunoXpert™, das neuartige Testverfahren der ersten Generation, ist bereits in Gebrauch und hat sich an Tausenden von Patienten bewährt*. Das Testverfahren der zweiten Generation umfasste die Entwicklung einer neuen patientennahen Diagnoseplattform, die einfach zu handhaben ist und nur 15 Minuten Zeit in Anspruch nimmt. "Diese Zusammenarbeit wird uns ermöglichen, die Fertigstellung unserer patientennahen Diagnoseplattform zu beschleunigen", sagte Dr. med. Kfir Oved, CTO bei MeMed. "Die neue Plattform ermöglicht nicht nur innerhalb von Minuten Messungen unserer bakteriellen Tests im Vergleich zu viralen Tests, sondern ebnet darüber hinaus den Weg zu einer Vielzahl von Mehrfach-Proteinmessungen in Form von Schnelltests mit der Präzision einer Labordiagnostik für einen umfassenden Anwendungsbereich." "Das Projekt wird außerdem unser Testmenü zum frühen Erkennen von Infektionen bewerten und erweitern, sogar bereits in einem präsymptomatischen Krankheitsstadium, in dem noch keine Symptome vorliegen. Dies stellt zurzeit eine enorme Einschränkung unserer Fähigkeit dar, Infektionen und Epidemien unter Kontrolle zu halten", stellte Dr. Tanya Gottlieb, VP Scientific Affairs bei MeMed, fest. Die Defense Threat Reduction Agency (DTRA) wurde im Jahr 1998 als eine dem Verteidigungsministerium der Vereinigten Staaten angeschlossene Behörde gegründet und befasst sich mit der Verminderung der Bedrohung durch Massenvernichtungswaffen. Die Hauptaufgabe der DTRA besteht darin, die Bedrohung der Vereinigten Staaten und der restlichen Welt durch globale Massenvernichtungswaffen sowie improvisierte Bedrohungen einzudämmen. Dies geschieht durch Integration, Synchronisierung und die Bereitstellung von Fachwissen, Technologien und Fähigkeiten. Weitere Informationen zur DTRA erhalten Sie unter http://www.dtra.mil. MeMed engagiert sich für die Verbesserung der Lebensqualität von Patienten durch Forschung, Entwicklung und Vermarktung von bahnbrechenden Testverfahren, die den Immunstatus des Körpers überwachen. Die Tests von MeMed entschlüsseln die individuellen Reaktionen des Immunsystems auf unterschiedliche Gesundheits- und Erkrankungsstadien. Das Unternehmen konzentriert sich auf die Bereitstellung schneller, genauer und verfolgbarer Diagnostiklösungen für akute Infektionserkrankungen sowie Entzündungskrankheiten in Krankenhäusern und Gemeinden. ImmunoXpert™, das Testverfahren der ersten Generation des Unternehmens, hat die Fähigkeit bewiesen, genau zu erkennen, ob ein Patient an einer bakteriellen oder einer Viruserkrankung leidet. Dadurch werden Ärzte in die Lage versetzt, fundiertere Entscheidungen darüber zu treffen, ob eine Behandlung mit Antibiotika angezeigt ist. ImmunoXpert wurde für die klinische Verwendung in der Europäischen Union, der Schweiz und in Israel freigegeben. Zurzeit wird es in diesen Gebieten zu Proben verwendet. Eine weitere kommerzielle Verbreitung ist im Gang. Das Testverfahren der zweiten Generation von MeMed für schnelle Tests vor Ort (innerhalb von Minuten) befindet sich in der Entwicklung. Weitere Informationen erhalten Sie unter http://www.me-med.com.


"Wir freuen uns über diesen Vertrauensbeweis. Die Anerkennung unserer Arbeit durch die DTRA stärkt die Positionierung von MeMed als Weltmarktführer auf dem Gebiet der immunbasierten Diagnostik von Infektionskrankheiten", bemerkte Dr. Eran Eden, CEO bei MeMed.  "Diese gemeinsame Anstrengung und unsere wachsende Zusammenarbeit mit anderen internationalen Interessenvertretern aus Industrie und Regierung wird die weltweite Verfügbarkeit unserer Tests zur Bekämpfung antimikrobieller Resistenzen ermöglichen." Während der letzten acht Jahre haben die Unternehmensmitgründer Dr. med. Kfir Oved und Dr. Eran Eden mit führenden Forschern und Klinikern aus der ganzen Welt zusammengearbeitet, um die Veränderungen zu untersuchen, die im menschlichen Immunsystem stattfinden, wenn es Infektionen bekämpft, und um eine menschliche Immunsignatur zu entwickeln, die den Unterschied zwischen bakteriellen und Virusinfektionen genau erkennt. ImmunoXpert™, das neuartige Testverfahren der ersten Generation, ist bereits in Gebrauch und hat sich an Tausenden von Patienten bewährt*. Das Testverfahren der zweiten Generation umfasste die Entwicklung einer neuen patientennahen Diagnoseplattform, die einfach zu handhaben ist und nur 15 Minuten Zeit in Anspruch nimmt. "Diese Zusammenarbeit wird uns ermöglichen, die Fertigstellung unserer patientennahen Diagnoseplattform zu beschleunigen", sagte Dr. med. Kfir Oved, CTO bei MeMed. "Die neue Plattform ermöglicht nicht nur innerhalb von Minuten Messungen unserer bakteriellen Tests im Vergleich zu viralen Tests, sondern ebnet darüber hinaus den Weg zu einer Vielzahl von Mehrfach-Proteinmessungen in Form von Schnelltests mit der Präzision einer Labordiagnostik für einen umfassenden Anwendungsbereich." "Das Projekt wird außerdem unser Testmenü zum frühen Erkennen von Infektionen bewerten und erweitern, sogar bereits in einem präsymptomatischen Krankheitsstadium, in dem noch keine Symptome vorliegen. Dies stellt zurzeit eine enorme Einschränkung unserer Fähigkeit dar, Infektionen und Epidemien unter Kontrolle zu halten", stellte Dr. Tanya Gottlieb, VP Scientific Affairs bei MeMed, fest. Die Defense Threat Reduction Agency (DTRA) wurde im Jahr 1998 als eine dem Verteidigungsministerium der Vereinigten Staaten angeschlossene Behörde gegründet und befasst sich mit der Verminderung der Bedrohung durch Massenvernichtungswaffen. Die Hauptaufgabe der DTRA besteht darin, die Bedrohung der Vereinigten Staaten und der restlichen Welt durch globale Massenvernichtungswaffen sowie improvisierte Bedrohungen einzudämmen. Dies geschieht durch Integration, Synchronisierung und die Bereitstellung von Fachwissen, Technologien und Fähigkeiten. Weitere Informationen zur DTRA erhalten Sie unter http://www.dtra.mil. MeMed engagiert sich für die Verbesserung der Lebensqualität von Patienten durch Forschung, Entwicklung und Vermarktung von bahnbrechenden Testverfahren, die den Immunstatus des Körpers überwachen. Die Tests von MeMed entschlüsseln die individuellen Reaktionen des Immunsystems auf unterschiedliche Gesundheits- und Erkrankungsstadien. Das Unternehmen konzentriert sich auf die Bereitstellung schneller, genauer und verfolgbarer Diagnostiklösungen für akute Infektionserkrankungen sowie Entzündungskrankheiten in Krankenhäusern und Gemeinden. ImmunoXpert™, das Testverfahren der ersten Generation des Unternehmens, hat die Fähigkeit bewiesen, genau zu erkennen, ob ein Patient an einer bakteriellen oder einer Viruserkrankung leidet. Dadurch werden Ärzte in die Lage versetzt, fundiertere Entscheidungen darüber zu treffen, ob eine Behandlung mit Antibiotika angezeigt ist. ImmunoXpert wurde für die klinische Verwendung in der Europäischen Union, der Schweiz und in Israel freigegeben. Zurzeit wird es in diesen Gebieten zu Proben verwendet. Eine weitere kommerzielle Verbreitung ist im Gang. Das Testverfahren der zweiten Generation von MeMed für schnelle Tests vor Ort (innerhalb von Minuten) befindet sich in der Entwicklung. Weitere Informationen erhalten Sie unter http://www.me-med.com.


News Article | May 4, 2017
Site: www.prnewswire.com

Under the delivery order, Leidos will support the operation and maintenance of DTRA's MDS and NWP. This includes providing targeted research and development to identify and implement state-of-the-art techniques for improving environmental data used in DTRA's atmospheric transport and dispersion models for weapons of mass destruction and CBRNE accidental release predictions. Leidos will also provide improvements to the weather data collection and dissemination of weather products to DTRA's customers. "The Leidos team brings expertise in meteorology, developmental research, software engineering and system development to modernize and maintain DTRA's operational systems and weather product applications," said Leidos Group President, Mike Chagnon. "We are proud to support DTRA's critical CBRNE mission." Leidos is a global science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit www.Leidos.com. Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended December 30, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/defense-threat-reduction-agency-awards-leidos-13-million-contract-300451473.html


News Article | February 15, 2017
Site: www.24-7pressrelease.com

WEST PALM BEACH, FL, February 15, 2017-- Lt. General (Retired) Robert D. Chelberg has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are taken into account during the selection process.General Chelberg graduated from the United States Military Academy at West Point, New York, with a Bachelor of Science degree in 1961. Later in his military career he earned a Master of Business Administration degree from New Mexico State University. Based on academic achievements, he is a member of the Phi Eta Sigma and Phi Kappa Phi honor societies. He has attended all the normal military educational schools including the National War College in Washington, D.C. General Chelberg has been listed in the Marquis editions of Who's Who in America since 1993, and Who's Who in the World since 2007.He has held numerous positions of increasing responsibility in the U.S. Army during his 32-year career. He has commanded at all levels of the Field Artillery, and served two tours in Vietnam as the operations officer of three different battalions. He served for two years as 528th Artillery Group Commander in the early 1980s. This unit had the responsibility of protecting and assembling all the nuclear weapons in Turkey. His assignments in the Pentagon have included the Army Staff and the Office of the Secretary of Defense, where he was a Deputy Director for Military Personnel Policy.In 1986 he held the position of Executive to the Supreme Allied Command Europe (SACEUR). He then served as the Chief Defense Planner in the Supreme Headquarters of Allied Powers Europe (SHAPE), the headquarters for all the military forces of NATO. In September 1990, he was reassigned to Brussels, Belgium, to serve in the private office as a Special Advisor to the NATO Secretary General. He was promoted to Lieutenant General in January 1991, and then served as the Chief of Staff, U.S. European Command (EUCOM) in Stuttgart, Germany. During his time at EUCOM, the command participated in Desert Storm, Operation Provide Comfort to save 455,000 Kurdish people in Northern Iraq, and in other numerous relief and rescue contingency operations in Africa.General Chelberg retired on July 31, 1993 and subsequently assumed the duties of the Deputy Director of the George C. Marshall European Center for Security Studies. In conjunction with the German Government the school taught students from the former WARSAW Pact Nations and from the former Soviet Union. From the initial development and continuing for two years, he had budgetary, personnel, logistics, and construction responsibilities. For his performance at the Marshall Center, he was presented with the Decoration for Exceptional Civilian Service.His military decorations include: the Defense Distinguished Service Medal; the Army Distinguished Service Medal; two Defense Superior Service Medals; the Legion of Merit; five Bronze Stars; two Meritorious Service Medals; ten Air Medals; three Army Commendation Medals; and the Presidential Unit Citation (Navy).General Chelberg was named the 1986 Outstanding Alumnus of Lake Superior State University, and he was for 1985 the Veteran of the Year for VFW Post 3676. He was presented the Distinguished Eagle Scout Award in 1990. Only four percent of Eagle Scouts receive this honor. While in Europe, he served as District Commissioner for the Transatlantic Council Boy Scouts of America in the United Kingdom, France and Belgium from 1987-90, and was the council vice president for membership from 2004-08. He was inducted into New Mexico State University's Business School Hall of Fame in 2001.After military and civilian service of 34 years, General Chelberg has worked for Cubic Applications as a Managing Director in Europe and a Special Advisor in the U.S. For seven years, he promoted providing advice on organizational structure and computer assisted training exercises to former Warsaw Pact Nations.He has served as a Senior Fellow at the Joint Forces Staff College in Norfolk, Virginia from 2001 to 2011. In January 2003, General Chelberg accepted the position of Program Manager for the Defense Threat Reduction Agency (DTRA) Field Office located in Belgium. This organization had the responsibility of working nuclear, chemical and biological threats against SHAPE, NATO, and EUCOM. After spending three plus years in this position, he returned to the U.S., but made a number of trips in the next three years back to Europe to perform the role of a Senior Mentor for Foreign Consequence Management Exercises. These exercises were designed to develop solutions for weapons of mass destruction attacks made against NATO forces and NATO populations. During his time with DTRA and as a Senior Mentor, General Chelberg was employed by Northrop Grumman Information Systems. From 2010-16, he served as a senior advisor to TASC.He is a lifetime member of the Association of the United States Army, and the Military Officers Association of America. In the past he has been a member of Rotary International and was a Paul Harris Fellow. When he was in Europe in the mid 90's, he was a member of the Federation of German American Clubs, and served as the organization's president from 1994-96.General Chelberg currently serves as a volunteer President of sixteen volunteer Board Members for the Wounded Veterans Relief Fund which receives referrals from all the major Veterans Administration Medical Centers in Florida. This 501(c)3 organization provides temporary emergency financial needs to service connected disabled veterans who have served in our wars and conflicts since 9/11. The funds are paid to creditors to preclude eviction from a domicile for rent or mortgage payments, for electric, gas or water utilities, for car repair, license, insurance, and gas, home repairs, and other emergencies. Since 2014 over seven thousand veterans and their families have been assisted. The Military Officers Association of America presented their Community Hero's Assistance Award to the Wounded Veterans Relief Fund in October 2015.As for the future, Lt. General (Retired) Chelberg intends to continue serving his country and deserving veterans and assisting others as appropriate.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com


News Article | February 15, 2017
Site: phys.org

Understanding how carbon nanotubes (CNT) nucleate, grow and self-organize to form macroscale materials is critical for application-oriented design of next-generation supercapacitors, electronic interconnects, separation membranes and advanced yarns and fabrics. New research by LLNL scientist Eric Meshot and colleagues from Brookhaven National Laboratory (BNL) and Massachusetts Institute of Technology (MIT) has demonstrated direct visualization of collective nucleation and self-organization of aligned carbon nanotube films inside of an environmental transmission electron microscope (ETEM). In a pair of studies reported in recent issues of Chemistry of Materials and ACS Nano , the researchers leveraged a state-of-the-art kilohertz camera in an aberration-correction ETEM at BNL to capture the inherently rapid processes that govern the growth of these exciting nanostructures. Among other phenomena discovered, the researchers are the first to provide direct proof of how mechanical competition among neighboring carbon nanotubes can simultaneously promote self-alignment while also frustrating and limiting growth. "This knowledge may enable new pathways toward mitigating self-termination and promoting growth of ultra-dense and aligned carbon nanotube materials, which would directly impact several application spaces, some of which are being pursued here at the Laboratory," Meshot said. Meshot has led the CNT synthesis development at LLNL for several projects, including those supported by the Laboratory Directed Research and Development (LDRD) program and the Defense Threat Reduction Agency (DTRA) that use CNTs as fluidic nanochannels for applications ranging from single-molecule detection to macroscale membranes for breathable and protective garments. Explore further: 'Second skin' protects soldiers from biological and chemical agents More information: Viswanath Balakrishnan et al. Real-Time Imaging of Self-Organization and Mechanical Competition in Carbon Nanotube Forest Growth, ACS Nano (2016). DOI: 10.1021/acsnano.6b07251 Mostafa Bedewy et al. Measurement of the Dewetting, Nucleation, and Deactivation Kinetics of Carbon Nanotube Population Growth by Environmental Transmission Electron Microscopy, Chemistry of Materials (2016). DOI: 10.1021/acs.chemmater.6b00798


News Article | February 13, 2017
Site: www.rdmag.com

For the first time, Lawrence Livermore National Laboratory scientists and collaborators have captured a movie of how large populations of carbon nanotubes grow and align themselves. Understanding how carbon nanotubes (CNT) nucleate, grow and self-organize to form macroscale materials is critical for application-oriented design of next-generation supercapacitors, electronic interconnects, separation membranes and advanced yarns and fabrics. New research by LLNL scientist Eric Meshot and colleagues from Brookhaven National Laboratory(link is external) (BNL) and Massachusetts Institute of Technology (MIT) has demonstrated direct visualization of collective nucleation and self-organization of aligned carbon nanotube films inside of an environmental transmission electron microscope (ETEM). In a pair of studies reported in recent issues of Chemistry of Materials and ACS Nano, the researchers leveraged a state-of-the-art kilohertz camera in an aberration-correction ETEM at BNL to capture the inherently rapid processes that govern the growth of these exciting nanostructures. Among other phenomena discovered, the researchers are the first to provide direct proof of how mechanical competition among neighboring carbon nanotubes can simultaneously promote self-alignment while also frustrating and limiting growth. "This knowledge may enable new pathways toward mitigating self-termination and promoting growth of ultra-dense and aligned carbon nanotube materials, which would directly impact several application spaces, some of which are being pursued here at the Laboratory," Meshot said. Meshot has led the CNT synthesis development at LLNL for several projects, including those supported by the Laboratory Directed Research and Development (LDRD) program and the Defense Threat Reduction Agency (DTRA) that use CNTs as fluidic nanochannels for applications ranging from single-molecule detection to macroscale membranes for breathable and protective garments.


News Article | February 28, 2017
Site: www.eurekalert.org

ALBUQUERQUE, N.M. -- Agriculture consumes about 80 percent of all U.S. water. Making fertilizers uses 1 to 2 percent of all the world's energy each year. A new program hopes to develop better crops -- super plants that are drought-resistant, use less fertilizer and remove more carbon dioxide from the atmosphere. The program, ROOTS, or Rhizosphere Observations Optimizing Terrestrial Sequestration, is sponsored by the Department of Energy's Advanced Research Project Agency-Energy (ARPA-E). Sandia National Laboratories has received $2.4 million to adapt previously developed sensors to monitor root function and plant health in new, noninvasive ways through one ROOTS project. The insights gained from these sensors, with plant experts from The University of New Mexico (UNM) and the New Mexico Institute of Mining and Technology, will guide breeding of better varieties of sorghum. Sorghum is a drought-tolerant grain mostly grown for animal fodder and biofuels in the U.S. but relied upon as an important food crop in Africa and parts of Asia. The sensors will be easy to adapt to other crops too, said Eric Ackerman, manager of Sandia's Nanobiology department and principal investigator for the ROOTS project. Though roots are hard to access and study, thoroughly understanding how they work and how to improve them is essential for drought-resistant crops that need less fertilizer. Deep roots can tap additional water sources and extensive root systems can gather more nutrients, Ackerman said. Roots also are critical for depositing carbon into the soil, instead of the air. "It is really exciting to see how Eric Ackerman and his team are repurposing miniaturized sensing technologies originally developed for national security applications, such as warfighter health monitoring or detection of chemical agents for real-time monitoring of hard-to-access root systems," said Anup Singh, director of Sandia's Biological and Engineering Sciences Center. One technology researchers will adapt is a microneedle-based fluidic sensor. This matchbox-size device was originally developed for biomedical applications, such as the painless detection of electrolyte levels of warfighters on arduous missions. However, due to its size, minimally invasive set-up and ability to constantly measure the levels of important chemicals, Sandia researchers believe it's valuable for other research, such as plant monitoring. For the ROOTS project, researchers are interested in monitoring the products of photosynthesis, such as simple sugars, important root excretions, such as oxalic acid, and water pressure. Water pressure, or turgor pressure, is an important measure of plant health, even before they wilt. Current methods for measuring these critical indicators are costly, too invasive or don't provide continual data. "The microneedles will help us measure sugars transported by the plant to and from the roots before soil microbes can use them, and will give us a better understanding of how plants add to soil carbon," said Ben Duval, a plant and soil expert at the New Mexico Institute of Mining and Technology. Ronen Polsky, who leads the microneedles research, doesn't think the detection chemistry or the needles themselves will need much tweaking to work with plants, but one challenge will be determining the best way to attach the sensors to the plants. "The cool thing with our task on ROOTS," he said, "is that nobody has done this in plants before. It's such an intriguing project to take these sensors and apply them to plants." Initial support for developing the microneedle sensors came from Sandia's Laboratory Directed Research and Development program with additional funding by the Defense Threat Reduction Agency (DTRA). The sensor was also the subject of doctoral work by Philip Miller, currently a postdoctoral researcher at Sandia working on the ROOTS project. The other Sandia technology used in the ROOTS project is a micro gas chromatography system, or micro-GC. Sandia has been working on hand-held systems that detect and analyze gases indicative of chemical, biological and other threats for almost 20 years. For ROOTS, researchers will use the micro-GC systems to measure volatile organic compounds (VOC) above and in the ground. Ethylene, a common VOC that triggers fruit ripening, also can signal drought stress. Plants also use chemicals related to menthol and a component of eucalyptus smell as distress signals, for instance, if they are plagued by pests. UNM plant biologist Dave Hanson, co-principal investigator, said the "micro-GCs will be used to detect signals from environmental stress, such as drought, heat and nutrients, and biological stress, such as insect and pathogen attacks, as well as assess root growth." By placing very thin sample collection spikes in the ground and using cutting-edge detectors, Ron Manginell, who leads the micro-GC research, plans to monitor normal plant VOCs and these stress signals in almost real-time. "First, we have to figure out what the important VOCs actually are, which is always a challenging problem," Manginell said. "Once we figure out what those are, the challenge is putting together the miniaturized system to go after those." Then Manginell's team will take their prototype hand-held system and test it in the field. Initial support for developing the micro-GC system came from Sandia's Laboratory Directed Research and Development program with additional funding from the DOE, Defense Advanced Research Projects Agency and DTRA. Systems based on the same body of research are being used to analyze water quality and could be used to monitor diseases by just "smelling" a patient's breath, said Manginell. Sandia's project is one of 10 ROOTS projects funded by ARPA-E. Lawrence Berkeley National Laboratory and a number of universities will use other approaches and technologies to tackle the challenge of breeding better crops to reduce atmospheric carbon dioxide levels. "The microneedles and micro-GC developed by Sandia are extremely exciting because of their potential to provide critical data on plant function that have been unattainable in any setting," said Hanson. "If successful, these technologies will usher in a new era for research on plant function. They would also contribute to economic growth." Since both technologies are small, less expensive than alternatives and offer critical insights, the team hopes they could directly aid agricultural research and even commercial farming quickly and easily. Ackerman said, "The overall hope for Sandia is that this could open an important new national security area for the biology program to study beyond our current focus on bio-threats and biofuels. It brings us into the energy, water, climate, agriculture nexus, and we are hoping that there will be more opportunities in the future to use even more Sandia technologies." Sandia National Laboratories is a multimission laboratory operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corp., for the U.S. Department of Energy's National Nuclear Security Administration. With main facilities in Albuquerque, N.M., and Livermore, Calif., Sandia has major R&D responsibilities in national security, energy and environmental technologies and economic competitiveness.


News Article | February 10, 2017
Site: www.cemag.us

For the first time, Lawrence Livermore National Laboratory scientists and collaborators have captured a movie of how large populations of carbon nanotubes grow and align themselves. Understanding how carbon nanotubes (CNT) nucleate, grow and self-organize to form macroscale materials is critical for application-oriented design of next-generation supercapacitors, electronic interconnects, separation membranes, and advanced yarns and fabrics. New research by LLNL scientist Eric Meshot and colleagues from Brookhaven National and Massachusetts Institute of Technology has demonstrated direct visualization of collective nucleation and self-organization of aligned carbon nanotube films inside of an environmental transmission electron microscope (ETEM). In a pair of studies reported in recent issues of Chemistry of Materials and ACS Nano, the researchers leveraged a state-of-the-art kilohertz camera in an aberration-correction ETEM at BNL to capture the inherently rapid processes that govern the growth of these exciting nanostructures. Among other phenomena discovered, the researchers are the first to provide direct proof of how mechanical competition among neighboring carbon nanotubes can simultaneously promote self-alignment while also frustrating and limiting growth. "This knowledge may enable new pathways toward mitigating self-termination and promoting growth of ultra-dense and aligned carbon nanotube materials, which would directly impact several application spaces, some of which are being pursued here at the Laboratory," Meshot says. Meshot has led the CNT synthesis development at LLNL for several projects, including those supported by the Laboratory Directed Research and Development (LDRD) program and the Defense Threat Reduction Agency (DTRA) that use CNTs as fluidic nanochannels for applications ranging from single-molecule detection to macroscale membranes for breathable and protective garments.

Loading DTRA collaborators
Loading DTRA collaborators